Sarepta Therapeutics Zooms Higher on Early Data Rally Promising
Sarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
Steer clear of the worst practices in cryptocurrency investing to protect your assets. Learn from common mistakes.
12,710 articlesSarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
A 40-year-old Democrat who owns a fitness company focused on pregnant and postpartum women pulled off a tight victory...
NYSE has posted a listing for MSBT, a potential Morgan Stanley Bitcoin Trust. Market watchers say the bank’s first ba...
The Trump administration is weighing a measure to compensate TSA officers who have gone unpaid during a prolonged par...
Apple abandons the stalemate of building bigger AI models. In a bold pivot, the company opens iOS 27 to rival assista...
An experienced astronaut suddenly lost the ability to speak aboard the ISS, triggering a flurry of tests and question...
Markets rarely move in a straight line. This article analyzes the idea behind the prediction: trump bull market, what...
AMD posted a blowout Q1 FY2026 with record revenue and booming data-center sales. The company guides stronger-than-ex...
What can a millionaire interview teach you about building wealth? This article shares actionable routines, portfolio ...
A deep-dive look at electroCore's 2026 earnings narrative. This article unpacks Q1 signals, growth drivers, and pract...
IGIC's Q1 2026 results highlight growth momentum alongside margin pressure. This article breaks down the igic 2026 ea...
A 50-year-old professional earning $210,000 unveils a four-account plan to craft tax-free retirement income by 62, bl...